Concert Pharmaceuticals Inc is set to receive a $4 million milestone from GlaxoSmithKline Plc in connection with the selection of a lead HIV protease inhibitor for clinical development. The candidate drug will enter efficacy studies in 2012. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
